{
    "clinical_study": {
        "@rank": "151244", 
        "arm_group": {
            "arm_group_label": "chemoradiation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study was to evaluate the safety and efficacy of neoadjuvant concurrent\n      chemoradiation with weekly docetaxel/cisplatin in patients with resectable IIIA-N2 NSCLC."
        }, 
        "brief_title": "Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC", 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 18 years older.\n\n          -  Present with histologically proven or cytological diagnosis of NSCLC Stage IIIA as\n             defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer,\n             that is amenable to surgery.\n\n          -  No prior systemic chemotherapy or targeted therapy for lung cancer before screening.\n\n          -  ECOG performance status of 0 or 1.\n\n          -  Life expectancy \u226512 weeks.\n\n          -  Adequate hematological function:Absolute neutrophil count (ANC) \u22651.5 x 109/L, and\n             Platelet count \u2265100 x 109/L, and Hemoglobin \u22659 g/dL (may be transfused to maintain or\n             exceed this level).\n\n          -  Adequate liver function: Total bilirubin \u2264 1.5 x upper limit of normal\n             (ULN);Aspartate aminotransferase (AST), alanine aminotransferase (ALT) \u2264 2.5 x ULN in\n             subjects without liver metastases; \u2264 5 x ULN in subjects with liver metastases.\n\n          -  Adequate renal function:Serum creatinine \u2264 1.25 x ULN, and creatinine clearance \u2265 60\n             ml/min.\n\n          -  Female subjects should not be pregnant or breast-feeding.\n\n        Exclusion Criteria:\n\n          -  Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib,\n             gefitinib, cetuximab, trastuzumab).\n\n          -  Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g.\n             monoclonal antibody therapy).\n\n          -  History of another malignancy in the last 5 years with the exception of the\n             following:Other malignancies cured by surgery alone and having a continuous\n             disease-free interval of 5 years are permitted; Cured basal cell carcinoma of the\n             skin and cured in situ carcinoma of the uterine cervix are permitted.\n\n          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,\n             unstable angina, congestive heart failure, myocardial infarction within the previous\n             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic\n             disease).\n\n          -  Known hypersensitivity to Tarceva or gemcitabine or cisplatin.\n\n          -  Eye inflammation or eye infection not fully treated or conditions predisposing the\n             subject to this.\n\n          -  Evidence of any other disease, neurological or metabolic dysfunction, physical\n             examination or laboratory finding giving reasonable suspicion of a disease or\n             condition that contraindicated the use of an investigational drug or puts the subject\n             at high risk for treatment-related complications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01771289", 
            "org_study_id": "PKUPH-XW1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "chemoradiation", 
                "description": "weekly docetaxel/cisplatin combined with radiation", 
                "intervention_name": "docetaxel/cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "chemoradiation", 
                "description": "chemoradiation", 
                "intervention_name": "Radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Lung Cancer", 
        "lastchanged_date": "January 25, 2013", 
        "location": {
            "contact": {
                "email": "dr.yangf@gmail.com", 
                "last_name": "Fan Yang", 
                "phone": "+8688326657"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100000"
                }, 
                "name": "Peking university people's hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC", 
        "overall_contact": {
            "email": "Jwangmd@yahoo.com", 
            "last_name": "Jun Wang, MD", 
            "phone": "+8688324078"
        }, 
        "overall_contact_backup": {
            "email": "dr.yangf@gmail.com", 
            "last_name": "Fan Yang, MD", 
            "phone": "+8688326657"
        }, 
        "overall_official": {
            "affiliation": "Peking University People's Hospital", 
            "last_name": "Jun Wang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "downstage rate of mediastinal lymph nodes", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01771289"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University People's Hospital", 
            "investigator_full_name": "Jun Wang", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "5y"
            }, 
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "5y"
            }, 
            {
                "measure": "resection rate", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Peking University People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}